Carregant...
Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition
PURPOSE: Although KRAS represents the most commonly mutated oncogene, it has long been considered an “undruggable” target. Novel covalent inhibitors selective for the KRAS(G12C) mutation offer the unprecedented opportunity to target KRAS directly. However, prior efforts to target the RAS-MAPK pathwa...
Guardat en:
| Publicat a: | Clin Cancer Res |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7124991/ https://ncbi.nlm.nih.gov/pubmed/31776128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3523 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|